Shi Huimin, Yu Li, Shi Yun, Lu Jiaojiao, Teng He, Zhou Yifa, Sun Lin
Jilin Province Key Laboratory on Chemistry and Biology of Natural Drugs in Changbai Mountain, School of Life Sciences, Northeast Normal University, Changchun 130024, China.
Molecules. 2017 Jun 18;22(6):1016. doi: 10.3390/molecules22061016.
A rhamnogalacturonan I domain, named RG-I-3A, was prepared from ginseng pectin by pectinase digestion and chromatography separation. Monosaccharide composition analysis revealed that it was mainly composed of galacturonic acid, rhamnose, galactose, and arabinose in a molar ratio of 32.5:11.2:31.9:16.5, with a molecular weight of 50 kDa. Partial acid hydrolysis, monoclonal antibody detection, and NMR spectra analysis suggested RG-I-3A was composed of →4)-α-GalpA-(1→2)-α-Rhap-(1→disaccharide repeating units as backbone, with β-1,4-galactan, α-1,5-arabinan, AG-I, and AG-II side chains substituted via the O-4 of Rha. Galectin-3-mediated hemagglutination and biolayer interferometry assay indicated that RG-I-3A had inhibitory activity on galectin-3. These findings suggest the potential use of this ginseng RG-I domain as a galectin-3 inhibitor in drug development applications.
通过果胶酶消化和色谱分离从人参果胶中制备了一种鼠李半乳糖醛酸聚糖I结构域，命名为RG-I-3A。单糖组成分析表明，它主要由半乳糖醛酸、鼠李糖、半乳糖和阿拉伯糖组成，摩尔比为32.5:11.2:31.9:16.5，分子量为50 kDa。部分酸水解、单克隆抗体检测和核磁共振光谱分析表明，RG-I-3A由→4)-α-半乳糖醛酸-(1→2)-α-鼠李糖-(1→二糖重复单元作为主链，β-1,4-半乳聚糖、α-1,5-阿拉伯聚糖、AG-I和AG-II侧链通过鼠李糖的O-4位取代。半乳糖凝集素-3介导的血凝反应和生物层干涉测定表明，RG-I-3A对半乳糖凝集素-3具有抑制活性。这些发现表明，这种人参RG-I结构域在药物开发应用中作为半乳糖凝集素-3抑制剂具有潜在用途。
